Latest News
'25 at 25': Shortening treatment for tuberculosis
For our 25th anniversary celebrations, we look back at our clinical trials which have helped deliver shorter treatment regimens for the millions of people around the world who fall ill with tuberculosis every year.
New podcast episode: Who benefits most from a treatment?
In the latest episode of the Trial Talk podcast, Peter Godolphin and David Fisher discuss the new ‘within-trial framework for subgroup analysis’, as well as how other meta-analysis researchers can use it.
Excess inflammation linked to AIDS and other serious complications in adults on treatment for HIV
A sub-study from the START trial found that higher levels of inflammation averaged over the trial follow-up period were associated with a subsequent higher risk of AIDS, serious non-AIDS complications, or death during 6 years of continuous treatment for HIV. Delaying treatment resulted in higher levels of systemic inflammation during follow-up.
ODYSSEY confirms dolutegravir-based treatment is best for children living with HIV
New extended follow-up results from the global ODYSSEY clinical trial confirm that dolutegravir-based regimens are superior to other antiretroviral treatments for children living with HIV.
'25 at 25': Optimising treatments for people with cancer
As part of our 25th anniversary celebrations, we explore our trials that aim to improve quality of life by optimising treatments for people with cancer.